Elephas Announces $41.5 Million In Series B Funding
09/06/22, 4:15 PM
Location
madison
Money raised
$41.5 million
Industry
biotechnology research
Round Type
series b
Elephas Biosciences Corporation (Elephas), a private company, announced today that it has raised $41.5 million in Series B funding. ARCH Venture Partners led the round, and were joined by new investors, Moore Strategic Ventures and Tao Capital Partners. Continuing investments were made by Northpond Ventures, Sands Capital, and WARF Ventures. Prior investments include $20 million from the Series A and $8 million from the founder and early seed investors.
Company Info
Location
madison, wisconsin, united states
Additional Info
Elephas is developing an ex-vivo technology suite to assess how live tumor fragments (LTFs) respond to immunotherapies. We seek to remove the trial-and-error approach to cancer care by harnessing the latest advances in cancer biology, advanced imaging, and artificial intelligence to accelerate drug development and empower clinical decision-making. Our unique approach maintains the native 3-dimensional cellular architecture and micro-environment of the tumor, enabling rapid real-time characterization of live tumor sample response to immunotherapies.